Microenvironmental Determinants of Therapy Response and Resistance 1

• 3429 Macrophages promote immunotherapy resistance of hepatocellular carcinoma through increasing tumor cell lipid availability Zhixian Liang, Xiaohang LONG, ZHEWEN XIONG, PATRICK WONG, Siyuan HUANG, Siyun Chen, Yiling Zhang, Lingyun ZHANG, Chunning Leung, Saiming Ngai, Stephen Lam CHAN, Alfred S. L. Cheng
• 3430 NR4A3 functions as an immuno-metabolic checkpoint in tumor-associated macrophages to mediate radiotherapy sensitivity in rectal cancer​ Xiaowan Guo, Gan Tao, Xiuli Guo, Kehua Hu, Rurui Xue, Yunli Mo, Hui Qiu, Qiuji Wu
• 3431 Neutrophil-like monocytes (NeuMos) with high levels of CXCL2 expression orchestrate systemic granulopoiesis and drive immunotherapy resistance in TNBC Fulya Alkan, Hilmi K. Alkan, Ahmet Caglayan, Aysun Caglayan, Aminah Lawal, Neva Celiker, Huidong Shi, Thomas Vogl, Nouri Neamati, Wicha Max, Hasan Korkaya
• 3432 · PDF Role of M2 macrophages in chemoresistance about the tumor microenvironment of epithelial ovarian cancer Jaesung Ryu, Baek MooJun, HyoWook Gil, Eunjung Yang, Kwangseock Kim, Taewan Kim, Kong Hyejeong, Beamjun Park, Seob Jeon
• 3433 · PDF A new classification of tumor-associated macrophages and their roles in resistance to immune checkpoint therapy Bryan T. Weselman, Satish Kumar Reddy Noonepalle, Manasa Suresh, Alexandra Singh, Isabella Duchovny, Xintang Li, Mackenna Ward, Alejandro Villagra
• 3434 Spatially resolved multi-omic profiling reveals BRCA-dependent immune remodeling during PARP inhibition and PD-L1 blockade Kenichi Shimada, Filipa Lynce, Claudine Isaacs, Xue Geng, Edward T. Richardson, Candace Mainor, Mei Wei, Julie M. Collins, Paula R. Pohlmann, Arielle L. Heeke, Kelly F. Zheng, Madeline Townsend, Lauren M. Sloat, Jane Staunton, Stuart J. Schnitt, Hongkun Wang, Joan S. Brugge, Geoffrey I. Shapiro, Jennifer L. Guerriero
• 3435 Spatial transcriptomic profiling reveals distinct tumor microenvironment remodeling patterns associated with immune checkpoint blockade response in lung adenocarcinoma Heesoo Yoon, Jin-Wook Choi, Sejoon Lee, Jin-Haeng Chung, Hyojin Kim
• 3436 · PDF Emerging evidence of cellular dormancy programs in non-small cell lung cancer (NSCLC) Grace Ha, Melissa Tracy, Anthony Griffen, Daniel Bravo, Dior Dedushi, Terence Li, David Schecter, Neel Chudgar, Chaoyuan Kuang, Julio Aguirre-Ghiso, Brendon Stiles, Lindsay M. LaFave
• 3437 · PDF Dynamic waves of anti-and pro-tumoral myeloid and Treg cells are generated in response to cyclophosphamide Andrea Franceschini, Giovanna Talarico, Davide Lombardi, Stefania Orecchioni, Giulia Bravetti, Iros Barozzi, Paolo Falvo, Francesco Bertolini
• 3438 · PDF DNA damaging therapies induce a pro-tumorigenic fibroblast phenotype Emily Lay, Mikal Negasi, Ben Flynn, Tressan Grant, Ioanna Kontou, Gernot Walko, Ute Jungwirth
• 3439 Albumin-bound paclitaxel induced stromal reprogramming drives PDAC resistance to AG neoadjuvant chemotherapy Haorui Li, Tiansuo Zhao, Xi Ma, Xiang He, Hongji Dai, Bin Wang
• 3441 · PDF Androgen-driven sexual dimorphism reshapes immune crosstalk and limits immunotherapy response in PDAC Sonia Mecorapaj, Tenzin Passang, Fanyuan Zeng, Zihan Chen, Shuhua Wang, Tuisha Gupta, Shayna Jankowski, Jian-Ming Li, Cynthia R. Giver, Swapnaa Balaji, Kiranj Chaudagar, Edmund K. Waller
• 3442 · PDF TiME evolution in the context of diffuse astrocytoma post-therapy relapse and progression Aliisa Tiihonen, Iida Salonen, Ella Raulamo, Eelis Mikkonen, Emilia Mäki, Maria Annala, Tomi Hoikka, Ismaïl Hermelo, Anna Dénes, Thomas Olsson Bontell, Helena Carén, Asgeir Jakola, Hannu Haapasalo, Kirsi Rautajoki
• 3443 · PDF Tumor and microenvironmental co-evolution in metastatic triple-negative breast cancer during immunotherapy Seongyeol Park, Manon de Graaf, Artem Lomakin, Zhicheng Ma, Noah F. Greenwald, Lise Mangiante, Clemens L. Weiss, Brennan Geti Simon, Michael Angelo, Marleen Kok, Christina Curtis
• 3444 Spatial profiling of recurrent glioblastoma in a Phase I clinical trial reveals favorable immune remodeling induced by intracerebroventricular CAR T therapy Wesley V. Wilson, MacLean P. Nasrallah, Nakial Cross, Yael A. Day, Vanessa Gonzalez, Rachel M. Leskowitz, Amy Marshall, Julie K. Jadlowsky, Gabriela Plesa, Donald L. Siegel, Elizabeth O. Hexner, Joseph A. Fraietta, Carl H. June, Stephen J. Bagley, Donald O’Rourke, Zev Binder, Andrew J. Rech
• 3445 · PDF Astrocytes reprogram radiation-resistant glioblastoma to reveal new therapeutic vulnerabilities Rana Abdelgawad, Andrew Dhawan
• 3446 · PDF Loxl2 drives neutrophil-mediated immune evasion and resistance to anti PD-1 therapy in murine melanoma Jiah Yang, Emre Arslan, Veena Kochat, Suresh Satpati, Kunal Rai
• 3447 Type III collagen regulated by stress signaling drives chemoresistance in pancreatic cancer by inducing tumor dormancy and remodeling the immunosuppressive niche Haiyan Xu, Yicheng Zhou, Shengbai Xue, Siming Wu, Liwei Wang
• 3448 · PDF Sequential senescence-escape cycles drive genomic heterogeneity and osimertinib resistance in EGFR-mutant NSCLC Nazia Jamil, Hayley McDaid, Howard D. Hosgood, Qualia Hooker, Nadjet Cornejal
• 3449 Heterogeneity in outcomes of cytokine blockade identifies plausible role for SPP1+macrophages in colorectal liver metastasis immune suppression Kristin Goodsell, Jason Carter, Sheela Damle, Xiuyun Jiang, Heidi Kenerson, Ian N. Crispe, Venu G. Pillarisetty
• 3450 · PDF Tumor mass dormancy - a potential driver of long-term persistent melanoma after immunotherapy? Yingxiao Shi, Zoltan Maliga, Tuulia Vallius, Shishir Pant, Roxanne Pelletier, Brigette Kobs, Priyanka Solanky, Yiwen He, Eliezer M. Van Allen, Sandro Santagata, Patrick Ott, Christine G. Lian, Elizabeth I. Buchbinder, David Liu, Peter Karl Sorger
• 3451 Single-cell transcriptomic insights into tumor and immune dynamics driving resistance to ixazomib combined with gemcitabine and doxorubicin in SMARCB1-deficient renal medullary carcinoma Kai Yu, Rebecca Tidwell, Tharakeswara Bathala, Rahul Sheth, Menuka Karki, Jianfeng Chen, Jing Qian, Fei Duan, Luigi Perelli, Melinda Soeung, Priya Rao, Arlene Siefker-Radtke, Najat Daw, Davis Ingram, Diana Shamsutdinova, Khalida Wani, Wei-Lien Wang, Alexander Lazar, Zilong Zhao, Sabitha Prabhakaran, Neus Bota, Andrew Futreal, Rare Tumor Initiative Team, Patient Mosaic Team, Liuqing Yang, Chunru Lin, Giannicola Genovese, Jianjun Gao, Linghua Wang, Nizar Tannir, Pavlos Msaouel
• 3452 Exploiting stromal vulnerabilities: NFATC2-expressing CAFs enhance chemotherapy sensitivity and reveal a targetable ERBB axis in pancreatic cancer Jiahao Guo, Samuele Cancellieri, Biswajyoti Sahu
• 3453 · PDF Macrophage polarization in ALK+ non-small cell lung cancer: Implications for treatment targeting Marisa E. Aikins, Abdullah Saeed, Derek Nancarrow, Peter J. Ulintz, Peggy Hsu, Yusoo Lee, Sofia Merajver, Kiran H. Lagisetty
• 3454 Dynamic alteration of ANXA2 expression as a predictor of response to neoadjuvant bevacizumab in newly diagnosed glioblastoma Taketo Ezaki, Ryota Tamura, Yohei Yamamoto, Jun Takei, Akihiko Teshigawara, Kyoichi Tomoto, Yasuharu Akasaki, Masahiro Toda, Yuichi Murayama, Hikaru Sasaki, Keisuke Miyake, Toshihide Tanaka
• 3455 POSTN-driven mechanotransduction sustains beta-catenin activity in CAFs to promote melanoma progression and drug resistance Jie Wang, Bruna DA SILVA SOLEY, Linli Zhou, Yuhang Zhang
• 3456 Spatial evolution of the tumor immune microenvironment between primary and recurrent serous ovarian cancer using a sixty plex multiplex immuno oncology panel Hayeon Shin, Jue young Kim, Yoon Joo Kim, Yookyung Lee, Jae-Hoon Kim
• 3457 · PDF Myeloid-derived suppressor cells mediate ferroptosis resistance in HR+/HER2- breast cancer via the ARID1A/AKR1C2 axis Guidong Chen, Jinpu Yu
• 3458 · PDF Targeting the CD44-SPP1 axis to overcome therapy resistance in bladder cancer Hiba Siddiqui, Yuzhen Zhou, Jihyun Lee, Kevin Bi, Jacqueline T. Ochoa, Martin Egger, Eliezer M. Van Allen, Filipe L. De Carvalho, Kent W. Mouw

在完整检索应用中浏览本分会场 →